WEDNESDAY, June 22 (HealthDay News) -- Commercially available botulinum neuromodulator, abobotulinumtoxinA, is significantly superior to onabotulinumtoxinA in the treatment of lateral orbital rhytids, according to a study published online June 20 in the Archives of Facial Plastic Surgery.
Kartik D. Nettar, M.D., from the Maas Clinic in San Francisco, and colleagues compared the efficacy of two commercially available botulinum neuromodulators, onabotulinumtoxinA and abobotulinumtoxinA, for the treatment of lateral orbital rhytids. A total of 90 patients were treated with 10 U of onabotulinumtoxinA on one side of face and 30 U of abobotulinumtoxinA on the contralateral side. Photographs were taken with a five-point photographic scale prior to the treatment, at 30 days, and at each visit.
The investigators found that both the patients and the investigators independently considered abobotulinumtoxinA to have a statistically significant advantage over onabotulinumtoxinA in the treatment of lateral orbital rhytids at maximal contraction. Patients preferred abobotulinumtoxinA over onabotulinumtoxinA 67 percent of the time. Although data and photographs showed evidence of abobotulinumtoxinA treating lateral orbital rhytids better at rest, this was not found to be statistically significant.
"AbobotulinumtoxinA showed a statistically significant superiority in efficacy with a dosage ratio used for this study of 3 U of abobotulinumtoxinA to 1 U of onabotulinumtoxinA," the authors write.
One of the study authors disclosed financial ties to Medicis Aesthetics Inc. (makers of abobotulinumtoxinA) and Allergan Inc. (makers of onabotulinumtoxinA). The study was funded by Medicis Aesthetics Inc.
Submit your opinion:
 | ||
| � | Join the Doctors Lounge online medical community
| |
No comments:
Post a Comment